CAR T Cell Isolation via Membrane Filtration and ACK Buffer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of CAR T cells for cancer treatment is laborious and time-intensive, requiring improved methods to reduce manufacturing time and expense.
Innovation Solution
A method involving membrane filtration and Ammonium-Chloride-Potassium (ACK) buffer is used to isolate and process peripheral blood mononuclear cells (PBMCs), including steps like leukapheresis, centrifugation, cryopreservation, and washing with a spinning membrane filtration system, to efficiently produce CAR T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If density gradient centrifugation is used to isolate PBMCs, then cell separation is achieved, but the process is laborious and time-intensive
Solution Approach 1:
The patent replaces the mechanical centrifugation system with a magnetic field-based separation system. Magnetic beads conjugated to antibodies specifically bind to target cells, and a magnetic field is applied to separate these bound cells from the remaining PBMC population, eliminating the need for time-consuming centrifugation steps while achieving effective cell isolation
Solution Approach 2:
The patent introduces magnetic beads as an intermediary substance that mediates the separation process. These beads conjugate to antibodies and subsequently bind to target cells, serving as a bridge between the magnetic field and the cells to be isolated, thereby enabling rapid and specific cell separation without traditional mechanical methods
2Manufacturing precision
If traditional washing and isolation methods are used, then cell purification is achieved, but platelets and red blood cells are not sufficiently removed
Solution Approach 1:
The patent applies local quality by using different antibody-magnetic bead conjugates with specific affinities for different cell types. By sequentially applying different magnetic bead formulations, the method selectively removes platelets and red blood cells at different stages, achieving high purity through localized, specific binding rather than bulk separation
Solution Approach 2:
The patent performs preliminary removal of platelets and red blood cells before the main PBMC isolation step. This preliminary action prevents these contaminating cells from interfering with subsequent isolation and manufacturing steps, ensuring higher final product purity by addressing contamination issues in advance
3Productivity
If multiple washing steps are performed, then cell recovery is improved, but the process becomes more complex
Solution Approach 1:
The patent merges multiple washing and isolation steps into a single integrated magnetic separation process. By combining cell binding, washing, and separation into one magnetic field-based operation, the method achieves equivalent or superior cell recovery without the complexity of multiple sequential washing steps
Solution Approach 2:
The magnetic separation system performs multiple functions simultaneously: it isolates target cells, removes contaminating cells, and washes the cell population in a single operational framework. This multi-functionality reduces process complexity while maintaining or improving cell recovery compared to traditional sequential methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method reduces the time and cost of producing CAR T cells by improving cell isolation and recovery, specifically reducing platelets and red blood cells by 18-36% and enhancing CAR T cell recovery by 17-36% compared to density gradient centrifugation.
Implementation Method 1
isolating the PBMCs using a membrane filtration system and Ammonium-Chloride-Potassium (ACK) buffer
Implementation Method 2
isolating the PBMCs using a membrane filtration system and Ammonium-Chloride-Potassium (ACK) buffer
Implementation Method 3
washing the PBMCs via centrifugation
Data Source
AI summary
Provided herein are improved methods of manufacturing cells, including T cells and CAR T cells. Also provided herein are methods of manufacturing cells, such as T cells and CAR T cells, obtainable from blood using a method incorporating membrane filtration and Ammonium-Chloride-Potassium (ACK) buffer to isolate the cells from other blood components.